- The following is an archived discussion of the DYK nomination of the article below. Please do not modify this page. Subsequent comments should be made on the appropriate discussion page (such as this nomination's talk page, the article's talk page or Wikipedia talk:Did you know), unless there is consensus to re-open the discussion at this page. No further edits should be made to this page.
The result was: promoted by Cwmhiraeth (talk) 05:48, 19 August 2017 (UTC)
| DYK toolbox |
|---|
Regrelor edit
Regrelor's chemical structure in 3D format, rotating.
- ... that regrelor (pictured), a new, experimental antiplatelet drug, was withdrawn during a phase II clinical trial due to an increased risk of bleeding? Source1: "Regrelor disodium had been in phase II clinical trials by Merck Sharp & Dohme for the treatment of thrombosis. But this research was discontinued due to the safety reasons." (ref1) and Source2: "Its clinical phase II was terminated due to bleeding complications." (Chackalamannil, S; Rotella, D; Ward, S. "Comprehensive Medicinal Chemistry III". p. 568)
Moved to mainspace by Biochemistry&Love (talk). Self-nominated at 01:14, 4 August 2017 (UTC).
New enough (Article moved from Draft:Regrelor on 3 August 2017), long enough (1,918 characters "readable prose size"), fully referenced. Hook fine, AGF on offline source. Image fine, has appropriate licence. Strongly recommend that the image be used. No QPQ required. Good to go. Hawkeye7 (talk) 22:41, 4 August 2017 (UTC)
